Expires on: 04/30/2024
The DC will perform basic research on leukaemia cell biology in vitro and in vivo at the Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel.
The project aims to investigate whether newly synthesized nuclear RAR and VDR ligands exhibit anticancer activity against acute myeloid leukaemia (AML) cells and whether this activity can be enhanced by cell-sensitizing compounds in vitro and in vivo. The major goal is to determine the ability of the ligand/sensitizer combinations to prevent AML relapse following chemotherapy-induced remission.
- The DC will perform in vitro experiments in commercially available and patient-derived AML cells to establish an efficacy profile of new nuclear receptor ligands and their possible synergy with sensitizing agents.
- The DC will test the compound combination(s) proved the most effective against leukaemia cells in culture using syngeneic mouse models of AML in vivo.
- The DC will work closely with other DCs and test novel compounds when available.
Qualifications
- Master’s degree in Biology, Biochemistry, Pharmacology, Medical Sciences, or a related subject.
- Experience with cell culture models, gene and protein expression assays, general molecular biology techniques.
- Knowledge of principles of cancer biology.
- Ability and readiness to perform animal studies.
- Willingness to train and supervise undergraduate and MSc students.
- Proficiency in written and spoken English (IELTS 6, CEFR B2 or equivalent; proof required).
- Applicants must be eligible to enrol on a 4 years PhD Programme at the host institution.